Cellectar Biosciences' Iopofosine I 131 Efficacy Data Accepted for ASCO Presentation
summarizeSummary
Cellectar Biosciences announced that efficacy results from a subset of its CLOVER WaM clinical trial for iopofosine I 131 in relapsed or refractory Waldenström Macroglobulinemia (r/r WM) patients have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in May-June 2026. This news follows a recent 10-K filing that raised substantial doubt about the company's ability to continue as a going concern, making any positive clinical development crucial. The company highlighted "highly encouraging" safety and efficacy results, suggesting iopofosine I 131 could address a significant unmet need in a patient population with no approved therapies. This creates a strong near-term catalyst for the stock as investors will anticipate the full data presentation. Investors should monitor the actual presentation of the CLOVER WaM data at ASCO (May 29 - June 2, 2026) for the complete efficacy and safety profile.
في وقت هذا الإعلان، كان CLRB يتداول عند ٢٫٩٩ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ١٢٫٧ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٢٫٤٣ US$ و٢٠٫٥٩ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٨ من 10. المصدر: GlobeNewswire.